09:12 AM EDT, 09/11/2025 (MT Newswires) -- Protagonist Therapeutics ( PTGX ) said Thursday that its partner, Johnson & Johnson ( JNJ ) , has submitted an application to the European Medicines Agency seeking approval of icotrokinra to treat moderate-to-severe plaque psoriasis in adults and adolescents above 12 years of age.

The investigational oral tablet selectively blocks the IL-23 receptor, which causes an inflammatory response in plaque psoriasis patients, Protagonist said.

The application is supported by data from four late-stage studies that met all primary and co-primary endpoints, the company said.

The EMA submission follows a New Drug Application filed with the US Food and Drug Administration in late July, the company added.